Prevalence of Prostatitis-Like Symptoms and Outcomes of NIH-CPSI in Outpatients with Lifelong and Acquired PE: Based on a Large Cross-Sectional Study in China
Table 2
Outcomes of PLS and NIH-CPSI in men with LPE/APE.
ALL ()
PE group ()
No PE group ()
value
LPE ()
APE
value
PLS
<0.001
<0.001
Mild (4–7)
134 (16.34%)
102 (20.48%)
32 (9.94%)
23 (16.20%)
79 (22.19%)
Moderate or severe (≥8)
91 (11.10%)
80 (16.06%)
11 (3.42%)
18 (12.68%)
62 (17.42%)
NIH-CPSI, scores
Total scores
<0.001
<0.001
Pain symptoms
<0.001
<0.001
Urinary symptoms
<0.001
<0.001
Quality of life impact
<0.001
<0.001
NIH-CPSI, scores
<0.001
<0.001
Mild (0–14)
622 (75.85%)
314 (63.05%)
308 (95.65%)
98 (69.01%)
216 (60.67%)
Moderate (15–30)
142 (17.32%)
128 (25.70%)
14 (4.35%)
32 (22.54%)
96 (26.97%)
Severe (31–43)
56 (6.83%)
56 (11.24%)
0 (0.00%)
12 (8.45%)
44 (12.36%)
PE = premature ejaculation; LPE = lifelong PE; APE = acquired PE; PLS = prostatitis-like symptoms; NIH-CPSI = National Institute of Health-Chronic Prostatitis Symptoms Index. Differences between PE and no PE groups were assessed by -test. Differences between LPE and APE were assessed by -test.
